Glycerophosphocholine
|
Basic information |
| Metabolite name | Glycerophosphocholine |
 | HMDB0000086 |
 |
C00670 |
 |
657272 |
| Synonyms | Glycerophosphate choline; |
| No. of studies | 34 |
|
Basic information |
| Metabolite name | Glycerophosphocholine |
| HMDB0000086 |
|
C00670 |
|
657272 |
| Synonyms | Glycerophosphate choline; |
| No. of studies | 34 |
|
Relationship between Glycerophosphocholine and depression (count: 34) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M044 | Type2 | CUMS + rTMS group vs. CUMS + sham rTMS group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M044 | Type3 | control + rTMS group vs. control + sham rTMS group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M050 | Type3 | 2h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M058 | Type1 | depressed HBV-infected patients group vs. control group and non-depressed HBV-infected group | Urine | Human | Down |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M081 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Down |
| Study M101 | Type1 | CSD group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M102 | Type1 | moderate MDD group vs. control group | Urine | Human | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | DG region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA3 region of hippocampus | ICR mouse | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell | Rat | Up |
| Study M1097 | Type1 | placebo-treated depression group vs. control group | Faece | Human | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M148 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Down |
| Study M148 | Type2 | CUMS + CSGS group vs. CUMS group | Liver | Wistar rat | Up |
| Study M148 | Type2 | CUMS + fluoxetine group vs. CUMS group | Liver | Wistar rat | Up |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Up |
| Study M458 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M473 | Type1 | high-fat diet group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M486 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M539 | Type2 | LPS+ Dl-3-n-butylphthalide group vs. LPS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M569 | Type2 | LPS + HPF group vs. LPS group | Serum | ICR mouse | Down |
| Study M598 | Type1 | MS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Nucleus accumbens | C57BL/6 J mouse | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Ventral hippocampus | C57BL/6 J mouse | Up |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Down |
| Study M712 | Type1 | depression group vs. control group | Hippocampus | Cynomolgus monkey | Up |
| Study M712 | Type1 | depression group vs. control group | Amygdala | Cynomolgus monkey | Up |
| Study M740 | Type1 | CUMS group vs. control group | Soleus muscle | Sprague-Dawley rat | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Down |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Frontal cortex | Wistar rat | Up |
| Study M867 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M883 | Type1 | MDD group vs. control group | Blood | Human | Up |
| Study M927 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M927 | Type2 | CUMS + Zhi-zi-chi decoction group vs. CUMS group | Brain | Sprague-Dawley rat | Down |